TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Fasting LDL-C at screening ≥ 100 mg/dL and ≤ 190 mg/dL~* Fasting triglycerides ≤ 150 mg/dL~* Body mass index (BMI) between 18.0 and 32.0 kg/m\^2~* Framingham cardiac risk score 10% or less~Exclusion Criteria:~* Treatment with a lipid-regulating drug or over the counter supplement in the last 3 months prior to screening~* History of coronary heart disease (CHD) or CHD equivalent~* Uncontrolled hypertension~* Diabetes mellitus

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and placebo tablets once a day for up to 8 weeks.
- Atorvastatin (Type: ACTIVE_COMPARATOR): Participants received placebo subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and 80 mg atorvastatin orally once a day for up to 8 weeks.
- Evolocumab (Type: EXPERIMENTAL): Participants received 420 mg evolocumab by subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and placebo tablets once a day for up to 8 weeks.
- Evolocumab and Atorvastatin (Type: EXPERIMENTAL): Participants received 420 mg evolocumab by subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and 80 mg atorvastatin orally once a day for up to 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~1. Type 1 ROP; defined as:~   * Zone I, any stage ROP with plus disease, or~  * Zone I, stage 3 ROP without plus disease, or~  * Zone II, stage 2 or 3 ROP with plus disease~2. No previous treatment for ROP in the study eye; no previous bevacizumab treatment in the non-study eye~Exclusion Criteria:~The following exclusions apply to the study eye:~1. Nasolacrimal duct obstruction~2. Major ocular anomalies (e.g., cataract, coloboma)~3. Any opacity that precludes an adequate view of the retina~If purulent ocular discharge is present in either eye, then the infant is ineligible.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- Bevacizumab 0.250 mg (Type: EXPERIMENTAL): Dosage of injected Bevacizumab to be studied
- Bevacizumab 0.125 mg (Type: EXPERIMENTAL): Dosage of injected Bevacizumab to be studied
- Bevacizumab 0.063 mg (Type: EXPERIMENTAL): Dosage of injected Bevacizumab to be studied
- Bevacizumab 0.031 mg (Type: EXPERIMENTAL): Dosage of injected Bevacizumab to be studied
- Bevacizumab 0.016 mg (Type: EXPERIMENTAL): Dosage of injected Bevacizumab to be studied
- Bevacizumab 0.008 mg (Type: EXPERIMENTAL): Dosage of injected Bevacizumab to be studied
- Bevacizumab 0.004 mg (Type: EXPERIMENTAL): Dosage of injected Bevacizumab to be studied
- Bevacizumab 0.002 mg (Type: EXPERIMENTAL): Dosage of injected Bevacizumab to be studied

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Doxycycline to Reduce Sputum MMP-9 Activity in Adult Cystic Fibrosis (CF) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cystic Fibrosis~* Hospitalization for Pulmonary exacerbation~Exclusion Criteria:~* Significant GI illness~* Participation in another Investigational Protocol~* Allergies to Doxycycline~* Sputum Culture only positive for Staphylococcus aureus,~* Pregnant or Nursing~* Unwilling to use effective birth control~* Elevated LFT's greater than 3x the upper limit of normal~* Creatinine greater than 1.5x the upper limit of normal~* Lung transplantation~* Substance abuse within 30 days of screening

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Patients given placebo twice a day for 8 days at beginning of inpatient CF exacerbation
- doxycycline (Type: ACTIVE_COMPARATOR): Patients given doxycycline 100 mg tablet twice a day for 8 days at the beginning of inpatient CF exacerbation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Magnesium Sulfate in Obese Preeclamptics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women who are ages 18-45~* 32-42 weeks' pregnant~* Prescribed magnesium sulfate for preeclampsia~* BMI ≥35 kg/m2~Exclusion Criteria:~* Pregnant women \< 32 weeks' pregnant~* Women who are on dialysis

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- MgSO4 4g load, 1g/hr infusion (Type: ACTIVE_COMPARATOR): Once their obstetrician prescribes magnesium sulfate, participant will be assigned by 50/50 chance to one of two treatment regimens. Participant will be assigned to either a dose of 4 g at the start, followed by 1g every hour; or a dose of 6 g at the start, followed by 2g every hour until treatment for preeclampsia is complete.
- MgSO4 6g load, 2g/hr infusion (Type: EXPERIMENTAL): Once their obstetrician prescribes magnesium sulfate, participant will be assigned by 50/50 chance to one of two treatment regimens. Participant will be assigned to either a dose of 4 g at the start, followed by 1g every hour; or a dose of 6 g at the start, followed by 2g every hour until treatment for preeclampsia is complete.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, 18-70 years of age;~* glioblastoma, confirmed histologically;~* no previous chemotherapy or radiotherapy for glioblastoma;~* non-methylated MGMT promoter in the tumor.~Exclusion Criteria:~* prior systemic treatment for glioblastoma multiforme;~* prior treatment with Avastin;~* significant cardiovascular disease;~* other active malignant disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* History of migraine (with or without aura) for ≥ 12 months prior to screening according to the International Headache Society (IHS) International Classification of Headache Disorders (ICHD-3) classification~* Migraine frequency: ≥ 4 and \< 15 migraine days per month on average across the 3 months prior to screening and during baseline~* Headache frequency: \< 15 headache days per month on average across the 3 months prior to screening and baseline~* Demonstrated at least 80% compliance with the eDiary.~Exclusion Criteria:~* Older than 50 years of age at migraine onset~* History of cluster headache or hemiplegic migraine headache~* Unable to differentiate migraine from other headache~* No therapeutic response with \> 2 medication categories for prophylactic treatment of migraine after an adequate therapeutic trial~* Used a prohibited medication, device, or procedure within 2 months prior to the start of the baseline phase or during the baseline phase~* Concomitant use of 2 or more medications with possible migraine prophylactic effects within 2 months prior to the start of the baseline phase or during the baseline phase. If only 1 prophylactic medication is used, the dose must be stable within 2 months prior to the start of the baseline phase and throughout the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo once a month (QM) by subcutaneous injection on day 1 and weeks 4, 8, 12, 16, and 20 in the 24-week double-blind treatment phase. At week 24, participants were re-randomized to receive either erenumab 70 mg or erenumab 140 mg, administered QM at weeks 24, 28, 32, 36, 40, 44, and 48, with actual dose blinded.
- Erenumab 70 mg QM (Type: EXPERIMENTAL): Participants received erenumab 70 mg QM by subcutaneous injection on day 1 and weeks 4, 8, 12, 16, and 20 in the 24-week double-blind treatment phase. At week 24, participants were re-randomized to receive either erenumab 70 mg or erenumab 140 mg, administered QM at weeks 24, 28, 32, 36, 40, 44, and 48, with actual dose blinded.
- Erenumab 140 mg QM (Type: EXPERIMENTAL): Participants received erenumab 140 mg QM by subcutaneous injection on day 1 and weeks 4, 8, 12, 16, and 20 in the 24-week double-blind treatment phase. At week 24, participants were re-randomized to receive either erenumab 70 mg or erenumab 140 mg, administered QM at weeks 24, 28, 32, 36, 40, 44, and 48, with actual dose blinded.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Extension to Bridging Study CTBM100C2303

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completed all visits in study CTBM100C2303, and visit 4 took place not more than 5 days before enrollment into this study.~* Confirmed diagnosis of cystic fibrosis participants with P. aeruginosa infection.~* Forced Expiratory Volume in One Second (FEV1) at screening (study CTBM100C2303) must be between 25% and 80% of normal predicted values.~Exclusion Criteria:~* Any use of inhaled anti-pseudomonal antibiotics between the termination of the core trial CTMB100C2303 and the enrollment into this study.~* Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Tobramycin Inhalation Powder (TIP) (Type: EXPERIMENTAL): Participants received 112 mg (four 28 mg capsules) of TIP administered by the T-326 Inhaler, twice a day (b.i.d.), given in a cycle of 28 days on treatment followed by 28 days off treatment (one cycle = 56 days) for up to 3 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Screening laboratory result indicating hepatitis C virus (HCV) Genotype-2 (GT2) infection.~* Chronic HCV infection.~* Subject must be HCV treatment-naïve (subject had never received a single dose of any approved or investigational regimen) or had failed prior interferon (IFN) or pegylated-interferon (pegIFN) ± ribavirin (RBV) or sofosbuvir (SOF) + RBV ± pegIFN therapy.~* Subject must be non-cirrhotic.~Exclusion Criteria:~* History of severe, life-threatening or other significant sensitivity to any excipient of the study drugs.~* Female who is pregnant, planning to become pregnant during the study, or breastfeeding; or male whose partner is pregnant or planning to become pregnant during the study.~* Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol in the opinion of the investigator.~* Positive test result at Screening for hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus antibody (HIV Ab).~* HCV genotype performed during screening indicating coinfection with more than 1 HCV genotype.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Arm A DB Active Drug (Type: EXPERIMENTAL): ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks (double-blind \[DB\] treatment period)
- Arm B DB Placebo (Type: EXPERIMENTAL): Placebo for ABT-493/ABT-530 QD for 12 weeks (DB treatment period)
- Arm B OL Active Drug (Type: EXPERIMENTAL): ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks (open-label \[OL\] treatment period)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Switching From TDF to TAF vs. Maintaining TDF in Chronic Hepatitis B With Resistance to Adefovir or Entecavir.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:All of below~1. Patient must have the ability to understand and sign a written informed consent form; consent must be obtained prior to initiation of study procedures~2. Male or female, 20 to 80 years of age~3. Compensated liver disease (Child-Pugh score \< 8)~4. HBsAg positive at least 6 months or more~5. HBeAg positive or negative~6. Confirmation of ETV resistance mutation (rt184, rtS202, or rtM250) at the enrollment of IN-US-174-0202 study, or ADV resistance mutation (rtA181V, rtA181T or rtN236T) at the enrollment of IN-US-174-0205 study~7. Completion of the week 240 visit in studies IN-US-174-0202 or 0205 study and maintained on TDF 300 mg QD~8. Patient is willing and able to comply with all study requirements~Exclusion Criteria: Any of below~1. Co-infection with HCV, HDV, HIV~2. Abusing alcohol (more than 40 g/day) or illicit drugs~3. Abnormal hematological and biochemical parameters, including:~1) serum bilirubin \>3 mg/dL 2) prothrombin time (INR) \>1.5 3) serum albumin \<2.8 g/dL 4) ascites, encephalopathy or variceal hemorrhage 5) Child-Pugh score ≥8~4. Received interferon or other immunomodulatory treatment for HBV infection in the 12 months before screening for this study~5. Medical condition that requires concurrent use of systemic corticosteroid or other immunosuppressive agent~6. Received solid organ or bone marrow transplant~7. Known hypersensitivity to study drugs, metabolites, or formulation excipients~8. Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the patient unsuitable for the study or unable to comply with dosing requirements~9. Use of investigational agents within 3 months of screening, unless allowed by the Sponsor or Investigator~10. A history of hepatocellular carcinoma (HCC) within 5 years of screening~11. A history treated malignancy (other than HCC) is allowable if the patient's malignancy has been in complete remission, off chemotherapy and without additional surgical intervention, during the preceding three years~12. Participation in another investigational drug trial~13. Pregnant or breastfeeding or willing to be pregnant

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Maintaining TAF monotherapy (Type: EXPERIMENTAL): - Tenofovir AlaFenamide (Vemlidy) Tablet, 25mg, Daily Oral, 96 weeks
- Switching from TDF to TAF (Type: ACTIVE_COMPARATOR): * Tenofovir Disoproxil Fumarate (Viread) Tablet, 300mg, Daily Oral, 48 weeks~* Tenofovir AlaFenamide (Vemlidy) Tablet, 25mg, Daily Oral, 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intra Oral Kinetics of Fluoride Containing Dentifrices

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Demonstrates understanding of the study procedures, restrictions and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form~* Aged 18-65 years~* Understands and is willing, able and likely to comply with all study procedures and restrictions~* Good general and mental health with, in the opinion of the investigator or medically qualified designee:~  1. No clinically significant and relevant abnormalities of medical history or oral examination~ 2. Absence of any condition that would impact on the participant's safety or well being or affect the individual's ability to understand and follow study procedures and requirements~* A minimum of 20 permanent natural teeth~* A gum-base stimulated whole saliva flow rate ≥ 0.8 mL/min and an unstimulated whole saliva flow rate ≥ 0.5 mL/min.~Exclusion Criteria:~* Pregnant or breast feeding women~* Presence of chronic debilitating disease.~* Any condition that causes xerostomia as determined by the Investigator.~* Evidence of untreated caries.~* Gross periodontal disease.~* Tongue or lip piercing or presence of dental implants. Professional tooth cleaning or dental treatment during study. Oral surgery or extraction within 6 weeks of the screening visit.~* Self reported oral symptoms including lesions, sores or inflammation~* Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients~* Currently taking antibiotics or have taken antibiotics within 2 weeks of the screening visit~* Any medication that could affect salivary flow or cause xerostomia as determined by the Investigator~* Use of multivitamins, calcium supplements and or fluoride supplements within 7 days of treatment phase~* Participant unwilling to abstain from smoking for at least 4 hours on the day of each test visit~* Recent history (within the last year) of alcohol or other substance abuse.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Test dentifrice (Type: OTHER): 1.5g (± 0.05g) of Test dentifrice followed by 10mL of de-ionised water rinse, then 10 mL orange juice rinse
- Reference dentifrice (Type: OTHER): 1.5g (± 0.05g) of Reference dentifrice followed by 10mL of de-ionised water rinse, then 10 mL water rinse
- Comparator dentifrice (Type: OTHER): 1.5g (± 0.05g) of Comparator dentifrice followed by 10mL of de-ionised water rinse, then 10 mL orange juice rinse

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of TAK-816 in Healthy Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female infants aged ≥3 and \<7 months (excluding hospitalized infants).~2. Infants whose legal acceptable representatives have given informed consent to the study prior to enrollment.~3. Infants whose parents or legal guardians have agreed to cooperate with the investigator during the study period.~Exclusion Criteria:~1. Any serious acute illness.~2. Any underlying cardiovascular, renal, hepatic, or hematologic disease, and/or developmental disorder.~3. History of possible Haemophilus influenzae type b (Hib) infection.~4. History of possible pertussis, diphtheria or tetanus infection.~5. Previously diagnosed immunodeficiency.~6. A documented history of anaphylaxis to any ingredient of the investigational products (TAK-816, ActHIB or DPT-TAKEDA).~7. A history of convulsions.~8. Previous administration of another Hib vaccine.~9. Previous administration of any other vaccine containing any of the components of polio, diphtheria, pertussis, or tetanus.~10. Treatment with any live vaccine during the 27 days before the first dose of TAK-816 or with any inactivated vaccine during the 6 days before dosing.

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 6 Months
- Healthy Volunteers: t

Study Arms:
- TAK-816 (Type: EXPERIMENTAL): None
- ActHIB (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete